American tennis player Coco Gauff recently addressed the Women’s Tennis Association’s (WTA) new policy on SRY gene-testing. This policy aims to ensure fair competition by restricting male participation in the women’s game. Gauff expressed support for the policy’s intent and the transgender community.
Gauff stated, “I understand the reasoning behind it. I think that this conversation has led to animosity toward the trans community, which I am not fond of. However, I also recognize the biological differences that need preservation.” She emphasized the importance of nuanced discussions on such topics.
Yes, I guess I kind of agree with trying to protect the fairness in women’s sports. But I also do not like the attack that it is creating for people who don’t really care but just want to use this as a reason to attack the trans community.
Following her first-round victory over Kayla Day at the National Open in Toronto, Gauff echoed the sentiments of top-ranked player Aryna Sabalenka. Sabalenka expressed, “I think it’s really important to keep the fairness in our tour. Biologically, men are stronger, so competing against biological men wouldn’t be fair for women.”
The WTA’s updated eligibility policy mandates a one-time SRY gene screening. The gene, present on the Y chromosome, contributes to male-typical development. Tests involve a cheek swab, blood test, or saliva sample. Players testing negative are immediately eligible for the WTA Tour, while a positive result requires further medical evaluation.
Players must sign a document stating that refusing testing could result in disciplinary action. The WTA asserts the policy is crafted to maintain equitable athletic opportunities and parity in women’s tennis.
WTA’s official policy on women’s eligibility emerged from member consultations and evolving sports standards reviews. The organization seeks to ensure fair competition for all WTA tournament participants.